jcm-logo

Journal Browser

Journal Browser

Advances in the Treatment of Glaucoma and Ocular Hypertension

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 20 January 2026 | Viewed by 443

Special Issue Editor


E-Mail Website
Guest Editor
Department of Ophthalmology, Jeju National University Hospital, Jeju-si, Republic of Korea
Interests: glaucoma; myopia; cataract surgery; ophthalmology; ocular hypertension; meta-analysis

Special Issue Information

Dear Colleagues,

We are thrilled to present "Clinical Advances in Glaucoma and Ocular Hypertension", a Special Issue of the Journal of Clinical Medicine aimed at consolidating the latest scientific evidence for the effective management of glaucoma and ocular hypertension.

Glaucoma remains the leading cause of irreversible blindness worldwide, and its prevalence is projected to increase in the coming years. As glaucomatous optic neuropathy is irreversible, early diagnosis and effective strategies to slow the progression of retinal ganglion cell damage are critical for preserving patients' vision and quality of life.

Recent years have witnessed remarkable advancements in the diagnosis and treatment of glaucoma and ocular hypertension. New imaging techniques have emerged to improve diagnostic accuracy, while innovative therapies, including novel IOP-lowering agents, drug delivery systems, neuroprotective strategies, and surgical approaches such as minimally invasive glaucoma surgery (MIGS), have been introduced. Furthermore, there is growing interest in the role of artificial intelligence in the management of glaucoma.

This Special Issue encompasses a broad range of topics and research methodologies aimed at establishing the most robust scientific evidence for managing glaucoma and ocular hypertension patients. Areas of focus include advancements in diagnostic tools, identification of risk factors, pharmacological and surgical treatments, MIGS, and the integration of artificial intelligence in glaucoma care. We welcome submissions across all levels of evidence, from original articles to systematic reviews. Contributions from diverse regions around the world are encouraged, and we eagerly look forward to receiving your valuable research.

Dr. Ahnul Ha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glaucoma
  • ocular hypertension
  • intraocular pressure (IOP)
  • minimally invasive glaucoma surgery (MIGS)
  • artificial intelligence (AI)
  • neuroprotection
  • meta-analysis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 962 KiB  
Article
Recent Changes in Trends of Nationwide Incidence of Glaucoma and Associated Visual Impairment in South Korea
by Sooyeon Choe, Chen Xi, Joonhyung Kim, Ahnul Ha and Young Kook Kim
J. Clin. Med. 2025, 14(16), 5691; https://doi.org/10.3390/jcm14165691 - 12 Aug 2025
Viewed by 192
Abstract
Background/Objectives: We analyzed recent changes in the incidence of glaucoma and associated visual impairment (VI) in Korea over a 16-year period. Methods: We utilized nationwide, longitudinal cohort data from the Korea National Health Insurance System (KNHIS) National Health Screening Cohort from 2004 to [...] Read more.
Background/Objectives: We analyzed recent changes in the incidence of glaucoma and associated visual impairment (VI) in Korea over a 16-year period. Methods: We utilized nationwide, longitudinal cohort data from the Korea National Health Insurance System (KNHIS) National Health Screening Cohort from 2004 to 2019 to evaluate the age-standardized incidence rate (SIR) of glaucoma and glaucoma-related VI. VI was determined based on KNHIS health examinations and the National Registry for Visual Disability. The incidence rates were estimated per 100,000 person-years. Joinpoint regression analysis was applied to assess significant changes in incidence trends, and subgroup analyses were conducted by age and sex. Results: The age-SIR of glaucoma increased from 864.1 per 100,000 in 2004 to a peak of 1101.1 in 2016, followed by a decline to 978.9 in 2019. Joinpoint regression identified a significant rise from 2007 to 2015 (annual percent change [APC]: +3.92%), with a subsequent decline (APC: –3.30%). The incidence of glaucoma-related severe VI decreased from 26.23 per 100,000 in 2004 to 8.76 in 2012, remaining stable thereafter at 12.49 in 2019. The VI-to-incidence ratio also declined from 0.030 in 2004 to 0.009 in 2012, which remained stable thereafter at 0.013 in 2019. Females consistently exhibited higher glaucoma incidence but lower VI rates than males. Conclusions: These recent trends highlight the evolving landscape of glaucoma epidemiology in Korea and underscore the need for sustained early detection efforts and optimized patient management. Full article
(This article belongs to the Special Issue Advances in the Treatment of Glaucoma and Ocular Hypertension)
Show Figures

Figure 1

Back to TopTop